Does the molecular subtype of breast cancer influence your decision to give hypofractionated radiotherapy?

I heard Jay Harris speak at ACRO last year and the Dana Farber/Brigham has a personalized BCT approach based on molecular subtype

‘Personalized’ BCT based on Subtype, Age (DFCI/BWH)

Luminals Age > 60: 266 x 16, no boost

Luminals Age 50-60: 266 x 15, 250 x 2

HER2+ Age > 50: 266 x 15, 250 x 4 < 50:...

At this point for patients who need breast RT only we do not distinguish based on phenotye for offering hypofractionation . Start B did not see any difference in outcome in any sub category. Whelan data when reviewed showed no difference in outcome for two fractionation for nottingham grade 3 diseas...

It’s not exactly obvious to me that there is any example where response to radiotherapy fraction size alone is affected by tumor grade alonewithin a particular disease subsite. This should be clearly distinguished from the potential/theoretical benefit of dose escalation in biologically-unfavorabl...

The new ASTRO guideline on whole breast fractionation recently published in Practical Radiation Oncology (PRO) recommended that the decision to offer hypofractionation should be independent of grade, ER, PR, Her2/neu status or margin status. There was 100% consensus on this question by the panel of ...